Store at 28C post-reconstitution, use within 28 days
Clinical evidence shows: 14 to 22% total body weight loss in clinical trials Preferential reduction of visceral (belly) fat over subcutaneous fat Improved insulin sensitivity within 4 to 8 weeks Reduced liver fat (NAFLD improvement) in 60 to 70% of patients Sustained appetite regulation
Recent regulatory approvals and positive clinical trial outcomes have validated the therapeutic potential of this drug class, demonstrating significant improvements in glycemic control and body weight reduction comparable to established injectable GLP-1 therapies
Delayed gastric emptying , documented on a scintigraphic gastric-emptying study
Tetanus can result from cuts, puncture wounds, or burns that become contaminated with the bacteria
Start your intake How Semaglutide May Affect Smoking Behavior Semaglutide works by activating GLP-1 receptors throughout the brain, including regions that regulate reward, impulse control, and cravings